Champlain Investment Partners LLC Grows Position in Neogen Co. (NASDAQ:NEOG)

Champlain Investment Partners LLC lifted its holdings in Neogen Co. (NASDAQ:NEOG) by 0.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,118,636 shares of the company’s stock after buying an additional 8,106 shares during the period. Champlain Investment Partners LLC owned approximately 3.28% of Neogen worth $86,420,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Harbour Investments Inc. acquired a new position in Neogen in the fourth quarter valued at approximately $27,000. Blue Trust Inc. lifted its holdings in Neogen by 196.7% during the 4th quarter. Blue Trust Inc. now owns 3,368 shares of the company’s stock worth $41,000 after buying an additional 2,233 shares in the last quarter. Covestor Ltd boosted its holdings in Neogen by 41.4% in the fourth quarter. Covestor Ltd now owns 4,103 shares of the company’s stock valued at $50,000 after purchasing an additional 1,202 shares during the period. KBC Group NV grew its position in shares of Neogen by 39.1% during the fourth quarter. KBC Group NV now owns 8,464 shares of the company’s stock worth $103,000 after buying an additional 2,379 shares in the last quarter. Finally, Brown Brothers Harriman & Co. grew its holdings in Neogen by 4,955.8% during the 4th quarter. Brown Brothers Harriman & Co. now owns 10,415 shares of the company’s stock worth $126,000 after acquiring an additional 10,209 shares in the last quarter. 96.73% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Neogen

In related news, CAO John Patrick Moylan bought 10,000 shares of the stock in a transaction on Thursday, April 10th. The shares were bought at an average cost of $5.07 per share, for a total transaction of $50,700.00. Following the purchase, the chief accounting officer now owns 10,000 shares of the company’s stock, valued at $50,700. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. 1.13% of the stock is owned by insiders.

Wall Street Analyst Weigh In

NEOG has been the subject of a number of recent analyst reports. Piper Sandler decreased their price target on Neogen from $13.00 to $6.50 and set a “neutral” rating for the company in a report on Monday. Guggenheim cut their target price on Neogen from $15.00 to $13.00 and set a “buy” rating on the stock in a research report on Thursday, April 10th.

Neogen Stock Performance

NASDAQ NEOG opened at $4.60 on Thursday. Neogen Co. has a 1 year low of $3.87 and a 1 year high of $18.58. The company has a debt-to-equity ratio of 0.33, a current ratio of 3.77 and a quick ratio of 2.46. The company has a market capitalization of $997.94 million, a PE ratio of -2.10 and a beta of 1.57. The company has a fifty day moving average of $8.74 and a two-hundred day moving average of $11.76.

Neogen (NASDAQ:NEOG) last released its quarterly earnings results on Wednesday, April 9th. The company reported $0.10 EPS for the quarter, missing the consensus estimate of $0.12 by ($0.02). The firm had revenue of $221.00 million for the quarter, compared to analyst estimates of $225.27 million. Neogen had a positive return on equity of 2.89% and a negative net margin of 52.12%. The company’s quarterly revenue was down 3.4% on a year-over-year basis. During the same period last year, the firm earned $0.12 EPS. As a group, analysts expect that Neogen Co. will post 0.38 earnings per share for the current year.

About Neogen

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.